Evidence map›Paper›PMID 35912717›Full record

ArticleActa ophthalmologica2023

Correlation of vascular and fluid-related parameters in neovascular age-related macular degeneration using deep learning.

Markus Schranz, Reinhard Told, Valentin Hacker, Gregor S Reiter, Adrian Reumueller, Wolf-Dieter Vogl, Hrvoje Bogunovic, Stefan Sacu, Ursula Schmidt-Erfurth, Philipp K Roberts

Open access · hybridAbstract read
In one paragraph

Article in Acta ophthalmologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Markus SchranzVienna Clinical Trial Center (VTC), Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-2630-1368
Reinhard ToldDepartment of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0003-2046-7081
Valentin HackerVienna Clinical Trial Center (VTC), Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Gregor S ReiterDepartment of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-7661-4015
Adrian ReumuellerDepartment of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0003-4344-4624
Wolf-Dieter VoglOPTIMA, Christian Doppler Laboratory, Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Hrvoje BogunovicOPTIMA, Christian Doppler Laboratory, Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Stefan SacuVienna Clinical Trial Center (VTC), Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-4920-2231
Ursula Schmidt-ErfurthVienna Clinical Trial Center (VTC), Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-7788-7311
Philipp K RobertsDepartment of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATChristian Doppler Laboratory for Thermoelectricity · AT

Funding

Austrian Science Fund FWF KLI 749NCI NIH HHS
6 · The paper itself

Abstract

purposeTo identify correlations between the vascular characteristics of macular neovascularization (MNV) obtained by optical coherence tomography angiography (OCTA) and distinct retinal fluid volumes in neovascular age-related macular degeneration (nAMD).

methodsIn this prospective interventional study, 54 patients with treatment-naïve type 1 or 2 nAMD were included and treated with intravitreal aflibercept. At baseline and month 1, each patient underwent a SD-OCT volume scan and volumetric flow scan using a swept-source OCTA. A deep learning algorithm was used to automatically detect and quantify fluid in OCT scans. Angio Tool, a National Cancer Institute algorithm, was used to skeletonize MNV properties and quantify lesion size (LS), vessel area (VA), vessel density (VD), total number of endpoints (TNE), total number of junctions (TNJ), junction density (JD), total vessel length (TVL), average vessel length (AVL) and mean-e-lacunarity (MEL). Subsequently, linear regression models were used to investigate a correlation between OCTA parameters and fluid quantifications.

resultsThe median amount of fluid within the central 6-mm EDTRS ring was 173.7 nl at baseline, consisting of 156.6 nl of subretinal fluid (SRF) and 2.3 nl of intraretinal fluid (IRF). Fluid decreased significantly in all compartments to 1.76 nl (SRF) and 0.64 nl (IRF). The investigated MNV parameters did not change significantly after the first treatment. There was no significant correlation between MNV parameters and relative fluid decrease after anti-VEGF treatment. Baseline fluid correlated statistically significant but weakly with TNE (p = 0.002, R

conclusionMacular neovascularization parameters at baseline and month 1 played only a minor role in the exudation process in nAMD. None of the MNV parameters were correlated with the treatment response.

Indexed as

Deep LearningMacular DegenerationWet Macular DegenerationAngiogenesis InhibitorsFluorescein AngiographyHumansIntravitreal InjectionsProspective StudiesTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Identifiers

PMID35912717
PMCPMC10087766
OpenAlexW4289201635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.